Insight Molecular Diagnostics Q3 revenue beats, net loss narrows on cost cuts
Overview
US diagnostics technology firm's Q3 revenue rose, beating analyst expectations
Net loss for Q3 narrowed from prior year as operating expenses declined
Company progressing with FDA review of GraftAssureDx and preparing for commercial launch
Outlook
Company expects to submit FDA response for GraftAssureDx before Jan 21, 2027 deadline
FDA review clock for GraftAssureDx to restart upon submission, with about half of 150-day review remaining
Company continues to target outgoing free cash flow of about $8 mln in Q4 2026
Result Drivers
LAB SERVICES REVENUE - Most Q3 revenue came from laboratory services performed at the company's CLIA-certified lab in Tennessee
GALACTIC STUDY ENROLLMENT - Company expects GraftAssureCore testing revenue to build as enrollment in the GALACTIC registry study grows
COST REDUCTION - Operating and R&D expenses declined sequentially as costs related to GraftAssureDx FDA submission wound down
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Revenue | Beat | $559,000 | $244,200 (5 Analysts) |
Q3 Net Loss | $3.58 mln | ||
Q3 Pretax Loss | $3.58 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Insight Molecular Diagnostics Inc is $8.00, about 273.8% above its November 13 closing price of $2.14
Reuters Recommended Reads
Nov 16 - Larimar Therapeutics Q3 net loss narrows as R&D expenses fall
Nov 16 - Enanta Pharmaceuticals misses Q4 revenue estimates, posts wider net loss
Nov 16 - US FDA approves Roche's oral treatment for advanced breast cancer
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)